Drug Profile
KVD 001
Alternative Names: KVD-001Latest Information Update: 01 Dec 2022
Price :
$50
*
At a glance
- Originator Vantia Therapeutics
- Developer KalVista Pharmaceuticals
- Class Eye disorder therapies; Small molecules
- Mechanism of Action Plasma kallikrein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Diabetic macular oedema
Most Recent Events
- 30 Nov 2022 KVD 001 is still in phase II trials for Diabetic macular oedema in USA (KalVista Pharmaceuticals pipeline, November 2022)
- 29 Sep 2020 Phase II development is still ongoing for Diabetic macular oedema in USA (KalVista Pharmaceuticals pipeline, September 2020)
- 10 Feb 2020 KalVista Pharmaceuticals completes the option agreement with Merck for Diabetic macular oedema and future oral DME molecules